Avalo Therapeutics (AVTX) CMO exercises options, sells 679 pre-planned shares

Rhea-AI Filing Summary

Avalo Therapeutics Chief Medical Officer Doyle Mittie reported an option exercise and same-day share sale in Avalo Therapeutics, Inc. common stock. Mittie exercised stock options to acquire 679 shares of common stock at $8.04 per share, then sold 679 shares at $16.00 per share in an open-market transaction.

After these transactions, Mittie directly holds 3,622 shares of common stock and 148,329 stock options. The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025, indicating the timing was set in advance rather than decided on the trade date.

Insights

Equity compensation and insider trading analyst

Routine pre-planned option exercise and sale with modest scale vs. holdings.

The filing shows Chief Medical Officer Doyle Mittie exercising stock options for 679 shares at $8.04 and selling 679 shares at $16.00. This is a classic exercise-and-sell pattern, converting a small portion of equity compensation into cash.

Post-transaction, Mittie still directly holds 3,622 common shares and 148,329 options, so only a small slice of the total equity exposure changed. A footnote confirms the trades were executed under a Rule 10b5-1 trading plan adopted on November 13, 2025, suggesting the timing was pre-scheduled rather than opportunistic.

The stock option award itself vests 25% on January 28, 2026 with the remainder vesting monthly over three years, tying compensation to continued service. Overall, this looks like routine compensation management rather than a thesis-changing event.

Insider Trade Summary 10b5-1

Net Seller: 679 shares ($10,864)

Net Sell 3 txns

Insider Doyle Mittie

Role Chief Medical Officer

Sold 679 shs ($11K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	679	$0.00	--
Exercise	Common Stock	679	$8.04	$5K
Sale	Common Stock	679	$16.00	$11K

Holdings After Transaction: Stock Option (Right to Buy) — 148,329 shares (Direct); Common Stock — 4,301 shares (Direct)

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Options exercised: 679 shares Exercise price: $8.04 per share Shares sold: 679 shares +5 more

8 metrics

Options exercised 679 shares Stock options exercised on April 1, 2026

Exercise price $8.04 per share Stock option exercise price for 679 shares

Shares sold 679 shares Common stock sold in open-market transaction on April 1, 2026

Sale price $16.00 per share Price for 679 Avalo Therapeutics common shares sold

Common shares held after 3,622 shares Direct Avalo Therapeutics common stock holdings post-transaction

Options remaining 148,329 options Stock options held following the reported exercise

Option expiration January 28, 2035 Expiration date of the stock option award

Initial vesting tranche 25% on January 28, 2026 First vesting date of the option grant

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), Exercise or conversion of derivative security, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

vesting financial

"vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doyle Mittie

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		M(1)		679	A	$8.04	4,301	D
Common Stock	04/01/2026		S(1)		679	D	$16	3,622	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.04	04/01/2026		M(1)			679	(2)	01/28/2035	Common Stock	679	$0	148,329	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

2. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Avalo Therapeutics (AVTX) report for Doyle Mittie?

Doyle Mittie exercised stock options for 679 Avalo Therapeutics shares and sold 679 shares the same day. The options were exercised at $8.04 per share and the shares were sold at $16.00 per share in an open-market transaction.

How many Avalo Therapeutics (AVTX) shares does Doyle Mittie hold after this Form 4?

After the reported transactions, Doyle Mittie directly holds 3,622 Avalo Therapeutics common shares. The Form 4 also shows 148,329 stock options remaining, providing additional potential equity exposure beyond the directly held common stock.

Was the Avalo Therapeutics (AVTX) insider trade by Doyle Mittie under a Rule 10b5-1 plan?

Yes. The filing states Mittie’s transactions were effected under a Rule 10b5-1 trading plan. The plan was adopted on November 13, 2025, indicating the trade timing was pre-arranged rather than decided on the transaction date.

What prices were involved in Doyle Mittie’s Avalo Therapeutics (AVTX) transactions?

Mittie exercised stock options at an exercise price of $8.04 and sold shares at $16.00. This reflects an exercise-and-sell pattern where derivative awards are converted into shares and then into cash at the prevailing market price.

What are the terms of Doyle Mittie’s Avalo Therapeutics (AVTX) stock option grant?

The stock option vests 25% on January 28, 2026, with the remainder vesting monthly over three years. The option has an exercise price of $8.04 and an expiration date of January 28, 2035, rewarding continued service over time.

Does Doyle Mittie still have unexercised Avalo Therapeutics (AVTX) stock options after this filing?

Yes. After exercising 679 options, Mittie still has 148,329 stock options reported outstanding. These options, with an exercise price of $8.04 and a January 28, 2035 expiration, represent significant remaining equity-linked compensation.